[1]王志玉,史爱云.雷珠单抗联合全视网膜激光光凝治疗重度非增生型糖尿病视网膜病变的疗效观察[J].眼科新进展,2017,37(8):776-779.[doi:10.13389/j.cnki.rao.2017.0197]
　WANG Zhi-Yu,SHI Ai-Yun.Ranibizumab combined with panretinal photocoagulation for severe non-proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(8):776-779.[doi:10.13389/j.cnki.rao.2017.0197]
点击复制

雷珠单抗联合全视网膜激光光凝治疗重度非增生型糖尿病视网膜病变的疗效观察/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年8期
页码:
776-779
栏目:
应用研究
出版日期:
2017-08-05

文章信息/Info

Title:
Ranibizumab combined with panretinal photocoagulation for severe non-proliferative diabetic retinopathy
作者:
王志玉; 史爱云
355000　福建省福安市，福建省宁德市闽东医院眼科(王志玉)；355000　福建省福安市，福建省宁德市闽东医院消化内科(史爱云)
Author(s):
WANG Zhi-Yu; SHI Ai-Yun
Department of Ophthalmology，the Mindong Hospital of Ningde(WANG Zhi-Yu)，Fuan 355000，Fujian Province，China；Department of Gastroenterology，the Mindong Hospital of Ningde(SHI Ai-Yun)，Fuan 355000，Fujian Province，China
关键词:
雷珠单抗; 全视网膜光凝; 重度非增生型糖尿病视网膜病变; 疗效观察
Keywords:
ranibizuma; panretinal photocoagulation; severe non-proliferative diabetic retinopathy; efficacy observation
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2017.0197
文献标志码:
A
摘要:
目的　探讨雷珠单抗玻璃体内注射联合全视网膜激光光凝治疗重度非增生型糖尿病视网膜病变的临床疗效。方法　将本院2014年7月至2016年6月收治的重度非增生型糖尿病视网膜病变患者64例(90眼)，随机分为两组：对照组32例(44眼)单纯采用全视网膜激光光凝(panretinal photocoagulation，PRP)治疗，观察组32例(46眼)采用玻璃体内注射雷珠单抗联合PRP治疗，观察两组治疗前,治疗后1个月、3个月、6个月的最佳矫正视力(best corrected visual acuity，BCVA)、眼底、眼底荧光血管造影(fundus fluorescein angiography，FFA)、黄斑区视网膜神经上皮层厚度和黄斑区6 mm直径神经上皮总体容积，记录并计算治疗中的激光能量、光斑数和能量密度，对上述数据进行比较。结果　对照组和观察组患者治疗后1个月、3个月、6个月时 BCVA均优于治疗前(均为P＜0.05)，并且观察组患者治疗后1个月、3个月、6个月时 BCVA均优于对照组(均为P＜0.05)；对照组治疗后 6 个月时BCVA与治疗后 3 个月比较，差异无统计学意义(P＞0.05)，其他时间点比较差异均有统计学意义(均为P＜0.05)；观察组治疗后各时间点比较差异均有统计学意义(均为P＜0.05)。黄斑区视网膜神经上皮层平均厚度和黄斑区6 mm直径神经上皮总体容积的对比中，对照组和观察组治疗前后比较、治疗后两组中不同时间点之间比较差异均有统计学意义(均为P＜0.05)。并且观察组患者治疗后1个月、3个月、6个月时黄斑区视网膜神经上皮层厚度、黄斑区6 mm直径神经上皮总体容积均优于对照组(均为P＜0.05)。观察组在激光能量、光斑数和能量密度均显著低于对照组（均为P＜0.05）。结论　玻璃体内注射雷珠单抗联合PRP治疗重度非增生型糖尿病视网膜病变，利用较少的激光能量，可在较短时间内加快视网膜新生血管的消退、减轻黄斑水肿并改善患者的视功能，其疗效优于单纯应用PRP治疗，值得临床推广。
Abstract:
Objective　To evaluate the clinical efficacy of intravitreal injection of ranibizumab combined with panretinal photocoagulation for severe non-proliferative diabetic retinopathy.Methods　Sixty-four cases (90 eyes) with severe non-proliferative diabetic retinopathy from July 2014 to June 2016 in our hospital were randomly divided into two groups according to the digital table.The observation group (32 cases，46 eyes) underwent intravitreal injection of reizumab combined with panretinal photocoagulation,and the control group(32 cases，44 eyes) were treated with only panretinal photocoagulation．The visual acuity,fundus,fundus fluorescein angiography and macular thickness postoperative 1 month,3 months,6 months were observed and detected．The mean thickness of the retinal neuroepithelium in the macular region and total volume of the 6 mm diameter neuroepithelium in the macular area were compared and statistically analyzed.The laser energy,number of spots and energy density were calculated and recorded．Results　BCVA at postoperative 1 month,3 months,6 months in the observation and the control group were better than that before treatment(all P＜0.05),and the observation group was better than the control group (all P＜0.05).In the control group,BCVA had no statistically significant difference between 3 months and 6 months (P>0.05),and the differences were statistically significant among other time points (all P<0.05).In the observation group,the differences were statistically significant among all time points after treatment (all P<0.05).In the comparison of mean thickness of the retinal neuroepithelium in the macular region and total volume of the 6 mm diameter neuroepithelium in the macular area in the control group and the observation group before and after treatment,there were statistically significant differences at different time points between the two groups (all P<0.05).Moreover,the average thickness of the retinal neuroepithelium and total volume of 6 mm diameter neuroepithelium in the macular region at postoperative 1 month,3 months,6 months were better than those in the control group (all P<0.05).The laser energy,spot number and energy density of the observation group were significantly lower than those of the control group (all P<0.05).Conclusion　Intravitreal injection of ranibizumab combined with panretinal photocoagulation for severe non-proliferative diabetic retinopathy can accelerate retinal neovascularization in a short period of time,reduce macular edema and improve the visual function of patients with less laser energy,the curative effect is better than application of retinal laser photocoagulation alone,is worthy of clinical promotion.

参考文献/References:

［1］　PERENTE I，ALKIN Z，OZKAYA A，DARDABOUNIS D，OGREDEN TA，KONSTANTINIDIS A，et al.Focal laser photocoagulation in non-center involved diabetic macular edema［J］.Med Hypothesis Discov Innov Ophthalmol，2014，3(1)：9-16.
［2］　HEIER JS，KOROBELNIK JF，BROWN DM，SCHMIDT-ERFURTH U，DO DV，MIDENA E，et al.Intravitreal aflibercept for diabetic macular edema：148-week results from the VISTA and VIVID Studies［J］.Ophthalmology，2016，123(11)：2376-2385.
［3］　HUA W，CAO S，CUI J，MABERLEY D，MATSUBARA J.Analysis of reasons for noncompliance with laser treatment in patients of diabetic retinopathy［J］.Can J Ophthalmol，2013，48(2)：88-92.
［4］　SADIQ MA，SOLIMAN MK，SARWAR S，AGARWAL A，HANOUT M，DEMIREL S，et al.Effect of vitreomacular adhesion on treatment outcomes in the ranibizumab for edema of the macula in Diabetes(READ-3) Study［J］.Ophthalmology，2016，123(2)：324-329.
［5］　BROWN DM，NGUYEN QD，MARCUS DM，BOYER DS，PATEL S，FEINER L，et al.Long-term outcomes of ranibizumab therapy for diabetic macular edema：the 36-month results from two phase III trials：RISE and RIDE［J］.Ophthalmology，2013，120(10)：2013-2022.
［6］　PEARCE I，BANERJEE S，BURTON BJ，CHAKRAVARTHY U，DOWNEY L，GALE RP，et al.Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment：18-month，multicenter，phase IIIB RELIGHT Study［J］.Ophthalmology，2015，122(9)：1811-1819.
［7］　贺美华，罗先琼，杨洋，聂川，张嘉雯，梁志江，等.广东省早产儿视网膜病防治现状［J］.中华实用儿科临床杂志，2016，31(2)：105-107.
HE MH，LUO XQ，YANG Y，NIE C，ZHANG JW，LIANG ZJ，et al.Present situation of retinopathy in premature infants in Guangdong Province［J］.J Appl Clin Pediatr，2016，31(2)：105-107.
［8］　SCHMIDT-ERFURTH U，LANG GE，HOLZ FG，SCHLINGEMANN RO，LANZETT AP，MASSIN P，et al.Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema：the RESTORE extension study［J］.Ophthalmology，2014，121(5)：1045-1053.
［9］　LEE K，CHUNG H，PARK Y，SOHN J.Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography［J］.Korean J Ophthalmol，2014，28(4)：298-305.
［10］　COMYN O，SIVAPRASAD S，PETO T，NEVEU MM，HOLDER GE，XING W，et al.A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabeticmacular edema(the LUCIDATE study)［J］.Am J Ophthalmol，2014，157(5)：960-970.
［11］　ISHIBASHI T，LI X，KOH A，LAI TY，LEE FL，LEE WK，et al.The REVEAL Study：Ranibizumab Monotherapy or combined with laser versus laser monotherapy in asian patients with diabetic macular edema［J］.Ophthalmology，2015，122(7)：1402-1415.
［12］　LANG GE，BERTA A，ELDEM BM，SIMADER C，SHARP D，HOLZ FG，et al.Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema：interim analysis of the RESTORE extension study［J］.Ophthalmology，2013，120(10)：2004-2012.
［13］　李素华，高永峰.比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效［J］.眼科新进展，2015，35(6)：566-568，575.
LI SH，GAO YF.Efficacy of macular focal/grid photocoagulation combined with ranibizumab for diabetic macular edema［J］.Rec Adv Ophthalmol，2015，35(6)：566-568，575.
［14］　AL RASHAED S，AREVALO JF.Combined therapy for diabetic macular edema［J］.Middle East Afr J Ophthalmol，2013，20(4)：315-320.
［15］　MITRY D，BUNCE C，CHARTERIS D.Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion［J］.Cochrane Database Syst Rev，2013，31(1)：CD009510.
［16］　赵新荣，杨炜，邱明磊，张奕霞，蔡新雨，罗远湘.玻璃体内注射雷珠单抗联合玻璃体切割术治疗严重增生型糖尿病视网膜病变［J］.眼科新进展，2015，35(11)：1064-1066.
ZHAO XR，YANG W，QIU ML，ZHANG YX，CAI XY，LUO YX.Ranibizumab injection and vitrectomy for severe proliferative diabetic retinopathy［J］.Rec Adv Ophthalmol，2015，35(11)：1064-1066.
［17］　BRESSLER SB，GLASSMAN AR，ALMUKHTAR T，BRESSLER NM，FERRIS FL，GOOGE JM JR，et al.Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema［J］.Am J Ophthalmol，2016，164：57-68.
［18］　NOWACKA B，KIRKIEWICZ M，MOZOLEWSKA-PIOTROWSKA K，LUBISKI W.The macular function and structure in patients with diabetic macular edema before and after ranibizumabtreatment［J］.Doc Ophthalmol，2016，132(2)：111-122.
［19］　MITCHELL P，BRESSLER N，TOLLEY K，GALLAGHER M，PETRILLO J，FERREIRA A，et al.Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema：randomized clinical trial［J］.JAMA Ophthalmol，2013，131(10)：1339-1347.
［20］　ELMAN MJ，AYALA A，BRESSLER NM，BROWNING D，FLAXEL CJ，GLASSMAN AR，et al.Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment：5-year randomized trial results［J］.Ophthalmology，2015，122(2)：375-381.
［21］　王宇，周晓光，陈志均.早产儿视网膜病治疗研究进展［J］.中华实用儿科临床杂志，2017，32(2)：146-148.
WANG Y，ZHOU XG，CHEN ZJ.Advances in treatment of retinopathy of prematurit［J］.J Appl Clin Pediatr，2017，32(2)：146-148.
［22］　DO DV，NGUYEN QD，KHWAJA AA，CHANNA R，SEPAH YJ，SOPHIE R，et al.Ranibizumab for edema of the macula in diabetes study：3-year outcomes and the need for prolonged frequent treatment［J］.JAMA Ophthalmol，2013，131(2)：139-145.
［23］　COMYN O，LIGHTMAN SL，HYKIN PG.Corticosteroid intravitreal implants vs.ranibizumab for the treatment of vitreoretinal disease［J］.Curr Opin Ophthalmol，2013，24(3)：248-254.
［24］　FONG AH，LAI TY.Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema［J］.Clin Interv Aging，2013，8：467-483.
［25］　李秀娟.重复玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿［J］.中华眼外伤职业病杂志，2013，35(12)：887-889.
LI XJ.Consecutive intravitreal injection of Lucentis for the treatment of diabetic macular edema［J］.Chin J Ocul traum Occupat Eye Dis，2013，35(12)：887-889.
［26］　MARTINEZ-ZAPATA MJ，MART-CARVAJAL AJ，SOL I，PIJON JI，BUIL-CALVO JA，Cordero JA，et al.Anti-vascular endothelial growth factor for proliferative diabetic retinopathy［J］.Cochrane Database Syst Rev，2014，24(11)：CD008721.
［27］　王丽丽，张雯，李立婕，金丽英，霍敏，何斌.玻璃体内注射抗血管内皮生长因子单克隆抗体bevacizumab联合超全视网膜激光光凝治疗高危型糖尿病视网膜病变［J］.中华眼底病杂志，2010，26(2)：116-119.
WANG LL，ZHANG W，LI LJ，JIN LY，HUO M，HE B.Intravitreal injection with bevacizumab combined with extra panretinal photocoagulation for high-risk proliferative diabetic retinopathy［J］.Chin J Ocul Fund Dis，2010，26(2)：116-119.

相似文献/References:

[1]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[2]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[3]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].眼科新进展,2013,33(11):000.
[4]冯春阳.早期全视网膜光凝与复方樟柳碱球后穴位注射治疗缺血性视网膜中央静脉阻塞的疗效[J].眼科新进展,2010,30(5):000.
[5]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[6]张聪,刘东宁,徐丽. 玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效[J].眼科新进展,2014,34(9):864.[doi:10.13389/j.cnki.rao.2014.0239]
[7]章晖,叶波,邱新文,等.雷珠单抗辅助23G玻璃体切割术治疗增生性糖尿病视网膜病变[J].眼科新进展,2014,34(10):975.[doi:10.13389/j.cnki.rao.2014.0270]
[8]符敏,吴伟,唐罗生,等.糖尿病视网膜病变全视网膜光凝术后玻璃体视网膜界面的变化[J].眼科新进展,2014,34(11):1038.[doi:10.13389/j.cnki.rao.2014.0287]
　FU Min,WU Wei,TANG Luo-Sheng,et al.Changes of vitreoretinal interface in patients with proliferative diabetic retinopathy after panretinal photocoagulation[J].Recent Advances in Ophthalmology,2014,34(8):1038.[doi:10.13389/j.cnki.rao.2014.0287]
[9]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(8):246.[doi:10.13389/j.cnki.rao.2015.0066]
[10]刘斌,杨玉霞,刘杏,等. 雷珠单抗联合Ahmed青光眼阀植入术治疗新生血管性青光眼[J].眼科新进展,2015,35(3):263.[doi:10.13389/j.cnki.rao.2015.0070]
　LIU Bin,YANG Yu-Xia,LIU Xing,et al. Intravitreal lucentis injection combined with Ahmed valve implantation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(8):263.[doi:10.13389/j.cnki.rao.2015.0070]
[11]杨丽,唐慧.雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的临床观察[J].眼科新进展,2016,36(4):368.[doi:10.13389/j.cnki.rao.2016.0100]
　YANG Li,TANG Hui.Clinical study of intravitreal injection of ranibizumab and trabeculectomy with panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2016,36(8):368.[doi:10.13389/j.cnki.rao.2016.0100]
[12]雷祥,崔红培,李漫丽,等.雷珠单抗联合全视网膜光凝治疗缺血型视网膜中央静脉阻塞的疗效观察[J].眼科新进展,2019,39(1):041.[doi:10.13389/j.cnki.rao.2019.0009]
　LEI Xiang,CUI Hong-Pei,LI Man-Li,et al.Ranibizumab combined with panrentinal photocoagulation for the treatment of ischemic central retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(8):041.[doi:10.13389/j.cnki.rao.2019.0009]

更新日期/Last Update: 2017-08-14